Trial Profile
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary)
- Indications Axial spondyloarthritis
- Focus Therapeutic Use
- Acronyms COAST-Y
- Sponsors Eli Lilly and Company
- 15 Feb 2023 Results(n=932: from the COAST program at 3 years, 1 year of the originating studies (COAST-V/-W/-X) and 2 years of COAST-Y) assessing safety and efficacy of ixekizumab in patients with axial spondyloarthritis published in The Journal of Rheumatology
- 14 Nov 2022 Results assessing the recapture rates with Ixekizumab after withdrawal of therapy presented at the ACR Convergence 2022.
- 13 Sep 2022 Results(n=155) evaluating the recapture of response with open-label ixekizumab retreatment at week 104 in patients with axial spondyloarthritis who flared after withdrawal of IXE therapy pub, lished in the Annals of the Rheumatic Diseases